Cargando…
Sintilimab as maintenance treatment for local/regional recurrent esophageal squamous carcinoma after concurrent chemoradiotherapy: a single-arm Ib/II phase study
BACKGROUND: Esophageal cancer (EC) is an aggressive neoplasm of the gastrointestinal tract that is usually treated with a combination of chemotherapy, radiotherapy (RT), and/or surgery, according to disease status. Despite the availability of multimodal therapeutic strategies, local recurrence is fr...
Autores principales: | Liu, Chengxin, Sun, Hongfu, Huang, Wei, Wang, Zhongtang, Fu, Chengrui, Han, Dan, Zhao, Qian, Wu, Xue, Li, Baosheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264589/ https://www.ncbi.nlm.nih.gov/pubmed/37325650 http://dx.doi.org/10.3389/fimmu.2023.1193394 |
Ejemplares similares
-
Risk factors of esophageal fistula induced by re-radiotherapy for recurrent esophageal cancer with local primary site
por: Wang, Xinran, et al.
Publicado: (2022) -
Neoadjuvant sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: a single-arm phase 2 trial
por: Wei, Jia, et al.
Publicado: (2023) -
Concurrent chemoradiotherapy with S-1 compared with concurrent chemoradiotherapy with docetaxel and cisplatin for locally advanced esophageal squamous cell carcinoma
por: Zhou, Xi-Lei, et al.
Publicado: (2021) -
A new risk score model based on lactate dehydrogenase for predicting prognosis in esophageal squamous cell carcinoma treated with chemoradiotherapy
por: Liu, Chengxin, et al.
Publicado: (2023) -
Bone marrow dosimetric analysis of lymphopenia in patients with esophageal squamous cell carcinoma treated with chemoradiotherapy
por: Wang, Qian, et al.
Publicado: (2021)